NewLimit

Summary active Updated Jun 3, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location South San Francisco, CA
Founded 2021
Latest Stage Series C
Total Raised $610M+
Website https://newlimit.com/
Sector
biotech longevity healthcare ai drug-discovery

Investors

Nat Friedman Series C (2026)
Daniel Gross Series C (2026)
Patrick Collison Series B (2025)
Garry Tan Series A (angel) (2023)
Elad Gil Co-founder (2023)
John Collison Growth ($130M Series B) (2023)
Ilya Fushman Series A (2024)
Founders Fund Series C (2026)
Thrive Capital Series C (2026)
Greenoaks Capital Series C (2026)
Quiet Capital Series C (2026)
Kleiner Perkins Series C (2026)
Abstract Ventures Series C (2026)
Valor Equity Partners Series C (2026)
stripe Series B (2025)
Y Combinator Series A (angel) (2023)
NFDG Series C (returning, via NFDG) (2026)
gil-capital Co-founder (2023)

Founders

Jacob Kimmel Co-Founder, CEO & President
Brian Armstrong Co-Founder
Blake Byers Co-Founder

About

NewLimit is a South San Francisco-based longevity biotech developing epigenetic reprogramming medicines designed to restore youthful function in old cells and treat age-related diseases, founded in 2021 by Coinbase CEO Brian Armstrong, former GV partner and bioengineer Blake Byers, and stem-cell biologist Jacob Kimmel, who serves as CEO and President 12. The company uses an AI-driven genomics platform to discover combinations of transcription factors that reverse cellular aging, and plans to bring its first aging-reprogramming medicine — a therapy targeting old human liver cells — into human clinical trials in 2027 13. On June 2, 2026, NewLimit announced a $435 million Series C round led by Founders Fund that valued the company at approximately $3.1 billion post-money, roughly tripling its valuation from the prior year 123.

Funding History

Date Round Amount Lead Co-investors
2026-06-02 Series C $435M Founders Fund Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract Ventures, Valor Equity Partners, Eli Lilly Ventures, Human Capital, Nat Friedman, Daniel Gross 123

What Investors Say

No independently sourced investor quotes found at this time.

What Founders Say

No independently sourced founder quotes found at this time.

Sources

  1. NewLimit company blog, “NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trials,” June 2, 2026. Accessed June 2026. https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders↩↩↩↩

  2. STAT News, “Longevity startup NewLimit raises $435 million ahead of first clinical trial,” June 2, 2026. Accessed June 2026. https://www.statnews.com/2026/06/02/longevity-startup-newlimit-announces-435-million-clinical-trial-financing/↩↩↩

  3. Bitcoin.com News, “Coinbase CEO Brian Armstrong’s Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion,” June 2026. Accessed June 2026. https://news.bitcoin.com/newlimit-435-million-series-c-brian-armstrong/↩↩↩